Skip to main content
Clinical Trials/JPRN-jRCTs031230071
JPRN-jRCTs031230071
Completed
未知

An Exploratory study of safety and efficacy of the new chemical peeling

ogita Toshitatsu0 sites26 target enrollmentMay 15, 2023

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
ogita Toshitatsu
Enrollment
26
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

Increase in stratum corneum moisture content, confirming the peeling's action to improve stratum corneum moisture retention function. In the safety evaluation, these results suggest that the PLG-PML2-23-4 formulation is safe under normal use.

Registry
who.int
Start Date
May 15, 2023
End Date
July 12, 2023
Last Updated
2 years ago
Study Type
Interventional
Sex
Female

Investigators

Sponsor
ogita Toshitatsu

Eligibility Criteria

Inclusion Criteria

  • 1\)Those who have expressed their willingness to participate in the study, understood the explanation, and agreed in writing to participate in the study
  • 2\)Healthy Japanese women between the ages of 20 and 70 who wish to improve solar lentigines, freckle spots, chloasma, so\-called dullness, and who do not meet the exclusion criteria, regardless of the presence or absence of diseases such as pigment spots
  • 3\)Those who can fill in documents such as consent forms, questionnaires, usage diaries, etc.
  • 4\)Those who can come to the facility on the designated observation day

Exclusion Criteria

  • 1\)Subjects who are likely to be exposed to sunlight during the test period (daytime sports, etc.)
  • 2\)Subjects who are strongly aware of sensitive skin
  • 3\)Those who have experienced allergic symptoms due to cosmetics etc
  • 4\)Subjects with skin symptoms such as atopic dermatitis, seborrheic eczema, and vitiligo, and those with a history of them
  • 5\)Subjects with coagulation disorder, immune disorder, facial herpes, severe acne, eczema, etc.
  • 6\)Those with severe hay fever
  • 7\)Subjects with a history of serious liver disorder, renal disorder, or myocardial infarction
  • 8\)Those who are pregnant or during the study period, those who may become pregnant, and those who are breastfeeding
  • 9\)Subjects who received facial, high\-frequency treatment, injection treatment, etc. within 3 months from the start of the study
  • 10\)Those who participated in other clinical trials, research, etc. within 6 months of the start of the trial

Outcomes

Primary Outcomes

Not specified

Similar Trials